Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-ENHANCE trial of cannabidiol augmentation in first-episode psychosis
2025-521929-32-01Phase 3Authorised
- Sponsor
- University of Oxford
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in psychosis, schizophrenia, schizoaffective disorder and 1 more comparing Epidyolex adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change in total PANSS score. Planned start Jul 2026; status: authorised.
02
Drugs
cannabidiol
03
Conditions
psychosisschizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on 2025-521929-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521929-32-01.